FDA clears Boston Scientific to resume some defib distribution

April 16, 2010 by MassDevice staff

The Food & Drug Administration clears recent manufacturing changes made by by Boston Scientific Corp., partially resolving a notification glitch that had idled company's top-selling defibrillator implants for the past month.

BSX logo

Boston Scientific Corp. (NYSE:BSX) resumed U.S. shipments of its Cognis and Teligen defibrillators after federal regulators cleared recent changes to the company's manufacturing processes.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.